12 results on '"B-Cell Maturation Antigen immunology"'
Search Results
2. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
- Author
-
Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, and Tai YT
- Subjects
- Animals, Apoptosis, B-Cell Maturation Antigen genetics, Cell Proliferation, Drug Evaluation, Preclinical, Humans, Male, Mice, Mice, Inbred NOD, Mice, SCID, Multiple Myeloma immunology, Multiple Myeloma metabolism, Multiple Myeloma pathology, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, B-Cell Maturation Antigen immunology, CD8-Positive T-Lymphocytes immunology, Immunotherapy, Adoptive methods, Multiple Myeloma therapy, RNA, Messenger genetics, Receptors, Chimeric Antigen immunology
- Abstract
Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product, Descartes-08, with predictable pharmacokinetics for treatment of multiple myeloma. Descartes-08 is engineered by mRNA transfection to express anti-BCMA CAR for a defined length of time. Descartes-08 expresses anti-BCMA CAR for 1 week, limiting risk of uncontrolled proliferation; produce inflammatory cytokines in response to myeloma target cells; and are highly cytolytic against myeloma cells regardless of the presence of myeloma-protecting bone marrow stromal cells, exogenous a proliferation-inducing ligand, or drug resistance including IMiDs. The magnitude of cytolysis correlates with anti-BCMA CAR expression duration, indicating a temporal limit in activity. In the mouse model of aggressive disseminated human myeloma, Descartes-08 induces BCMA CAR-specific myeloma growth inhibition and significantly prolongs host survival (p < 0.0001). These preclinical data, coupled with an ongoing clinical trial of Descartes-08 in relapsed/refractory myeloma (NCT03448978) showing preliminary durable responses and a favorable therapeutic index, have provided the framework for a recently initiated trial of an optimized/humanized version of Descartes-08 (i.e., Descartes-11) in newly diagnosed myeloma patients with residual disease after induction therapy.
- Published
- 2021
- Full Text
- View/download PDF
3. Development of CAR-T cell therapies for multiple myeloma.
- Author
-
Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B, and Kröger N
- Subjects
- B-Cell Maturation Antigen immunology, Humans, Precision Medicine, Immunotherapy methods, Multiple Myeloma therapy, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen immunology
- Abstract
Currently available data on chimeric antigen receptor (CAR)-T cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) patients. The CAR-T field in MM is rapidly evolving with >50 currently ongoing clinical trials across all phases, different CAR-T design, or targets. Most of the CAR-T trials are performed in China and the United States, while European centers organize or participate in only a small fraction of current clinical investigations. Autologous CAR-T cell therapy against B cell maturation antigen shows the best evidence of efficacy so far but main issues remain to be addressed: duration of response, longer follow-up, prolonged cytopenia, patients who may benefit the most such as those with extramedullary disease, outcome prediction, and the integration of CAR-T cell therapy within the MM treatment paradigm. Other promising targets are, i.a.,: CD38, SLAMF7/CS1, or GPRC5D. Although no product has been approved to date, cost and production time for autologous products are expected to be the main obstacles for broad use, for which reason allogeneic CAR-T cells are currently explored. However, the inherent risk of graft-versus-host disease requires additional modification which still need to be validated. This review aims to present the current status of CAR-T cell therapy in MM with an overview on current targets, designs, and stages of CAR-T cell development. Main challenges to CAR-T cell therapy will be highlighted as well as strategies to structurally improve the CAR-T cell product, and thereby its efficacy and safety. The need for comparability of the most promising therapies will be emphasized to balance risks and benefits in an evidence-based but personalized approach to further improve outcome of patients with MM.
- Published
- 2020
- Full Text
- View/download PDF
4. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.
- Author
-
Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, Wen K, Hsieh PA, Kinneer K, Munshi N, Anderson KC, and Tai YT
- Subjects
- Apoptosis drug effects, Benzodiazepines administration & dosage, Cell Line, Tumor, DNA Damage, Drug Synergism, Humans, Multiple Myeloma genetics, Multiple Myeloma pathology, Pyrroles administration & dosage, Ataxia Telangiectasia Mutated Proteins antagonists & inhibitors, B-Cell Maturation Antigen immunology, Bortezomib therapeutic use, Cell Cycle Proteins antagonists & inhibitors, Immunoconjugates therapeutic use, Multiple Myeloma drug therapy, Protein-Tyrosine Kinases antagonists & inhibitors
- Abstract
To target mechanisms critical for multiple myeloma (MM) plasma cell adaptations to genomic instabilities and further sustain MM cell killing, we here specifically trigger DNA damage response (DDR) in MM cells by a novel BCMA antibody-drug conjugate (ADC) delivering the DNA cross-linking PBD dimer tesirine, MEDI2228. MEDI2228, more effectively than its anti-tubulin MMAF-ADC homolog, induces cytotoxicity against MM cells regardless of drug resistance, BCMA levels, p53 status, and the protection conferred by bone marrow stromal cells and IL-6. Distinctly, prior to apoptosis, MEDI2228 activates DDRs in MM cells via phosphorylation of ATM/ATR kinases, CHK1/2, CDK1/2, and H2AX, associated with expression of DDR-related genes. Significantly, MEDI2228 synergizes with DDR inhibitors (DDRi s) targeting ATM/ATR/WEE1 checkpoints to induce MM cell lethality. Moreover, suboptimal doses of MEDI2228 and bortezomib (btz) synergistically trigger apoptosis of even drug-resistant MM cells partly via modulation of RAD51 and accumulation of impaired DNA. Such combination further induces superior in vivo efficacy than monotherapy via increased nuclear γH2AX-expressing foci, irreversible DNA damages, and tumor cell death, leading to significantly prolonged host survival. These results indicate leveraging MEDI2228 with DDRi s or btz as novel combination strategies, further supporting ongoing clinical development of MEDI2228 in patients with relapsed and refractory MM.
- Published
- 2020
- Full Text
- View/download PDF
5. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
- Author
-
Shah N, Chari A, Scott E, Mezzi K, and Usmani SZ
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, B-Cell Maturation Antigen antagonists & inhibitors, B-Cell Maturation Antigen genetics, B-Cell Maturation Antigen immunology, B-Lymphocytes drug effects, B-Lymphocytes immunology, B-Lymphocytes pathology, Biomarkers, Tumor antagonists & inhibitors, Biomarkers, Tumor genetics, Biomarkers, Tumor immunology, Clinical Trials as Topic, Drug Resistance, Neoplasm genetics, Gene Expression, Humans, Molecular Targeted Therapy methods, Multiple Myeloma genetics, Multiple Myeloma immunology, Multiple Myeloma pathology, Recurrence, Treatment Outcome, Antibodies, Bispecific therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Immunoconjugates therapeutic use, Immunotherapy, Adoptive methods, Multiple Myeloma therapy
- Abstract
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there is no cure for MM, patients eventually become resistant to therapies, leading to development of relapsed/refractory MM. Therefore, an unmet need exists for MM treatments with novel mechanisms of action that can provide durable responses, evade resistance to prior therapies, and/or are better tolerated. B-cell maturation antigen (BCMA) is preferentially expressed by mature B lymphocytes, and its overexpression and activation are associated with MM in preclinical models and humans, supporting its potential utility as a therapeutic target for MM. Moreover, the use of BCMA as a biomarker for MM is supported by its prognostic value, correlation with clinical status, and its ability to be used in traditionally difficult-to-monitor patient populations. Here, we review three common treatment modalities used to target BCMA in the treatment of MM: bispecific antibody constructs, antibody-drug conjugates, and chimeric antigen receptor (CAR)-modified T-cell therapy. We provide an overview of preliminary clinical data from trials using these therapies, including the BiTE® (bispecific T-cell engager) immuno-oncology therapy AMG 420, the antibody-drug conjugate GSK2857916, and several CAR T-cell therapeutic agents including bb2121, NIH CAR-BCMA, and LCAR-B38M. Notable antimyeloma activity and high minimal residual disease negativity rates have been observed with several of these treatments. These clinical data outline the potential for BCMA-targeted therapies to improve the treatment landscape for MM. Importantly, clinical results to date suggest that these therapies may hold promise for deep and durable responses and support further investigation in earlier lines of treatment, including newly diagnosed MM.
- Published
- 2020
- Full Text
- View/download PDF
6. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications.
- Author
-
Bae J, Parayath N, Ma W, Amiji M, Munshi N, and Anderson KC
- Subjects
- Drug Delivery Systems methods, Humans, Lymphocyte Activation immunology, Polylactic Acid-Polyglycolic Acid Copolymer, B-Cell Maturation Antigen immunology, CD8-Positive T-Lymphocytes immunology, Cancer Vaccines, Multiple Myeloma, Nanoparticles chemistry
- Abstract
The purpose of these studies was to develop and characterize B-cell maturation antigen (BCMA)-specific peptide-encapsulated nanoparticle formulations to efficiently evoke BCMA-specific CD8
+ cytotoxic T lymphocytes (CTL) with poly-functional immune activities against multiple myeloma (MM). Heteroclitic BCMA72-80 [YLMFLLRKI] peptide-encapsulated liposome or poly(lactic-co-glycolic acid) (PLGA) nanoparticles displayed uniform size distribution and increased peptide delivery to human dendritic cells, which enhanced induction of BCMA-specific CTL. Distinct from liposome-based nanoparticles, PLGA-based nanoparticles demonstrated a gradual increase in peptide uptake by antigen-presenting cells, and induced BCMA-specific CTL with higher anti-tumor activities (CD107a degranulation, CTL proliferation, and IFN-γ/IL-2/TNF-α production) against primary CD138+ tumor cells and MM cell lines. The improved functional activities were associated with increased Tetramer+ /CD45RO+ memory CTL, CD28 upregulation on Tetramer+ CTL, and longer maintenance of central memory (CCR7+ CD45RO+ ) CTL, with the highest anti-MM activity and less differentiation into effector memory (CCR7- CD45RO+ ) CTL. These results provide the framework for therapeutic application of PLGA-based BCMA immunogenic peptide delivery system, rather than free peptide, to enhance the induction of BCMA-specific CTL with poly-functional Th1-specific anti-MM activities. These results demonstrate the potential clinical utility of PLGA nanotechnology-based cancer vaccine to enhance BCMA-targeted immunotherapy against myeloma.- Published
- 2020
- Full Text
- View/download PDF
7. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- Author
-
D'Agostino M and Raje N
- Subjects
- B-Cell Maturation Antigen immunology, Humans, Receptors, Chimeric Antigen, B-Cell Maturation Antigen antagonists & inhibitors, Immunotherapy, Adoptive methods, Multiple Myeloma therapy
- Abstract
Despite a substantial survival improvement and the availability of many new drugs in the last 2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic approaches are changing the current landscape in MM with B-cell maturation antigen (BCMA) as one of the most promising target antigens. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA produced unprecedented results in heavily pretreated relapsed and/or refractory MM. Data on more than 300 MM patients treated with anti-BCMA directed CAR T cells are available and these numbers are rapidly increasing. The response rate and the depth of responses induced by anti-BCMA CAR T cells are impressive; however, the majority of patients eventually relapse. Understanding the underlying mechanisms of response and resistance in treated MM patients will be critical to the rational development of this therapy. Moreover, the ideal place of this therapy in the treatment paradigm for MM is an important question that needs biological and clinical correlative data to help elucidate. T-cell-related, tumor-related and microenvironmental factors may play a role in the efficacy of anti-BCMA CAR T-cell therapy. In this review we summarize key clinical and correlative data on anti-BCMA CAR T-cell therapy. Based on available data we will try to highlight opportunities to further optimize this potential game-changing therapy for MM.
- Published
- 2020
- Full Text
- View/download PDF
8. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 + cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.
- Author
-
Bae J, Samur M, Richardson P, Munshi NC, and Anderson KC
- Subjects
- Cell Line, Tumor, Humans, Immunotherapy, Adoptive methods, Vaccination methods, B-Cell Maturation Antigen immunology, CD8-Positive T-Lymphocytes immunology, Cytotoxicity, Immunologic immunology, Multiple Myeloma immunology, Multiple Myeloma therapy, T-Lymphocytes, Cytotoxic immunology
- Abstract
To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138
+ tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a key myeloma-associated antigen. The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8+ CTL that mediate effective and long-lasting immunity against MM. Here we report the identification of novel engineered peptides specific to BCMA, BCMA72-80 (YLMFLLRKI), and BCMA54-62 (YILWTCLGL), which display improved affinity/stability to HLA-A2 compared to their native peptides and induce highly functional BCMA-specific CTL with increased activation (CD38, CD69) and co-stimulatory (CD40L, OX40, GITR) molecule expression. Importantly, the heteroclitic BCMA72-80 specific CTL demonstrated poly-functional Th1-specific immune activities [IFN-γ/IL-2/TNF-α production, proliferation, cytotoxicity] against MM, which were correlated with expansion of Tetramer+ and memory CD8+ CTL. Additionally, heteroclitic BCMA72-80 specific CTL treated with anti-OX40 (immune agonist) or anti-LAG-3 (checkpoint inhibitor) display increased immune function, mainly by central memory CTL. These results provide the framework for clinical application of heteroclitic BCMA72-80 peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors.- Published
- 2019
- Full Text
- View/download PDF
9. Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
- Author
-
Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, and Tice DA
- Subjects
- Drug Evaluation, Preclinical methods, Humans, Antibodies immunology, B-Cell Maturation Antigen immunology, Benzodiazepines pharmacology, Multiple Myeloma drug therapy, Pyrroles pharmacology, Stem Cells drug effects
- Published
- 2019
- Full Text
- View/download PDF
10. A compound chimeric antigen receptor strategy for targeting multiple myeloma.
- Author
-
Chen KH, Wada M, Pinz KG, Liu H, Shuai X, Chen X, Yan LE, Petrov JC, Salman H, Senzel L, Leung ELH, Jiang X, and Ma Y
- Subjects
- Animals, B-Cell Maturation Antigen immunology, Cell Line, Tumor, Cytotoxicity, Immunologic immunology, Humans, K562 Cells, Male, Mice, Mice, Inbred NOD, Neoplasm Recurrence, Local immunology, Receptors, Antigen, T-Cell immunology, Signaling Lymphocytic Activation Molecule Family immunology, T-Lymphocytes immunology, Xenograft Model Antitumor Assays methods, Multiple Myeloma immunology, Receptors, Chimeric Antigen immunology
- Abstract
Current clinical outcomes using chimeric-antigen receptors (CARs) against multiple myeloma show promise in the eradication of bulk disease. However, these anti-BCMA (CD269) CARs observe relapse as a common phenomenon after treatment due to the reemergence of either antigen-positive or -negative cells. Hence, the development of improvements in CAR design to target antigen loss and increase effector cell persistency represents a critical need. Here, we report on the anti-tumor activity of a CAR T-cell possessing two complete and independent CAR receptors against the multiple myeloma antigens BCMA and CS1. We determined that the resulting compound CAR (cCAR) T-cell possesses consistent, potent and directed cytotoxicity against each target antigen population. Using multiple mouse models of myeloma and mixed cell populations, we are further able to show superior in vivo survival by directed cytotoxicity against multiple populations compared to a single-expressing CAR T-cell. These findings indicate that compound targeting of BCMA and CS1 on myeloma cells can potentially be an effective strategy for augmenting the response against myeloma bulk disease and for initiation of broader coverage CAR therapy.
- Published
- 2018
- Full Text
- View/download PDF
11. Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients.
- Author
-
Bera TK, Abe Y, Ise T, Oberle A, Gallardo D, Liu XF, Nagata S, Binder M, and Pastan I
- Subjects
- Antibodies, Monoclonal immunology, Cell Line, Cell Line, Tumor, HEK293 Cells, Humans, B-Cell Maturation Antigen immunology, Immunotoxins immunology, Multiple Myeloma immunology, Recombinant Fusion Proteins immunology
- Published
- 2018
- Full Text
- View/download PDF
12. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
- Author
-
Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, and Friedrich M
- Subjects
- Animals, Apoptosis, Cells, Cultured, Cytokines metabolism, Female, Humans, Lymphocyte Activation, Macaca fascicularis, Mice, Multiple Myeloma immunology, Multiple Myeloma pathology, Xenograft Model Antitumor Assays, Antibodies, Bispecific therapeutic use, B-Cell Maturation Antigen immunology, CD3 Complex immunology, Multiple Myeloma therapy, T-Lymphocytes immunology
- Abstract
B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ɛ (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA-positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.